



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

H.P. Acthar Gel Renewal

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Form with two columns: Patient Name and Prescriber Name. Fields include HPP Member Number, Date of Birth, Address, City, State ZIP, Patient Primary Phone, Line of Business (Medicaid, CHIP), Fax, Office Contact, NPI, Promise ID, Prescriber PA PROMISe ID, Address, City, State ZIP, and Specialty/facility name (if applicable).

Expedited/Urgent checkbox

Drug Name:

Strength:

Days Supply:

Number of Refills:

Directions / SIG:

HPP's maximum approval time is 12 months but may be less depending on the drug.

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Has the patient been previously approved for H.P. Acthar Gel?

Yes checkbox

No checkbox

Q2. Has the patient been compliant with taking H.P Acthar Gel?

Yes checkbox

No checkbox

Q3. Has the patient been tolerating H.P Acthar Gel without any significant side effects?

Yes checkbox

No checkbox

Q4. Has the patient experienced resolution of symptoms/clinical improvement while receiving H.P. Acthar Gel treatment? (Please attach supporting documentation showing the response to prior treatment.)

Yes checkbox

No checkbox

Q5. Does the patient have any of the following contraindications: (scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, sensitivity to proteins of porcine origin, or administration of live or live attenuated vaccines in patients receiving immunosuppressive doses of H.P. Acthar Gel)?

Yes checkbox

No checkbox

Q6. For infantile spasms, is the patient less than 2 years of age?

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

H.P. Acthar Gel Renewal

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:

Prescriber Name:

[] Yes

[] No

Q7. For infantile spasms, does the patient have a suspected congenital infection?

[] Yes

[] No

Q8. For infantile spasms, is H.P. Acthar Gel going to be used as monotherapy?

[] Yes

[] No

Q9. For acute exacerbation(s) of Multiple Sclerosis, is documentation attached that the patient is currently being treated with a disease modifying drug for multiple sclerosis (such as Copaxone, Tecfidera, Aubagio)? Please note these medications require prior authorization.

[] Yes

[] No

Q10. For acute exacerbation(s) of Multiple Sclerosis, is H.P. Acthar Gel being used to treat an acute exacerbation of Multiple Sclerosis and therefore is not being used as "pulse therapy" (defined as use on a once monthly or routine basis to prevent MS exacerbations)?

[] Yes

[] No

Q11. For Rheumatic Disorders, is the patient currently receiving maintenance treatment for the condition (such as non-biologic DMARDs, TNF inhibitor, or other biologic medication)? (Please provide documentation).

[] Yes

[] No

Q12. Does the patient require treatment beyond the initial approved duration? (Please attach progress notes demonstrating the need for continued treatment along with the planned taper schedule.)

[] Yes

[] No

Q13. Requested Duration:

[] 3 months

Q14. Additional Information:

Prescriber Signature

Date

Updated 2018